Home・Aktien・Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Open

BrancheGesundheitswesen

6.56 0.61

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.43

Max

6.79

Schlüsselkennzahlen
By Trading Economics
Einkommen	32M -47M
Verkäufe	28M 99M
EPS	-0.11
Gewinnspanne	-47.642
Angestellte	975
EBITDA	32M -39M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+31.01% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	972M 2.9B
Vorheriger Eröffnungskurs	5.95
Vorheriger Schlusskurs	6.56

Nachrichtenstimmung

By Acuity

50%

152 / 340 Ranking in Healthcare

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares rise amid positive social media discussions and analyst projections of over $400 million in revenue this year.

11. Aug. 2026, 23:46 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid volatility. No specific news was identified to explain the price movement.

10. Aug. 2026, 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

7. Aug. 2026, 20:03 UTC

News

Social Media

Iovance Biotherapeutics rises as Barclays and Citizens raise price targets amid positive sentiment and high trading volume.

6. Aug. 2026, 20:03 UTC

Social Media

News

Iovance Biotherapeutics reported record Q2 revenue of $99.3 million, exceeding estimates. The stock is higher amid strong demand and FDA Fast Track Designation for SAR-201.

5. Aug. 2026, 23:16 UTC

Iovance Biotherapeutics shares are higher in after-market trading, reflecting broader market strength amid falling crude oil prices and strong corporate earnings.

4. Aug. 2026, 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3. Aug. 2026, 19:51 UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31. Juli 2026, 23:41 UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30. Juli 2026, 23:51 UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29. Juli 2026, 15:16 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28. Juli 2026, 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27. Juli 2026, 19:36 UTC

Social Media

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24. Juli 2026, 19:12 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22. Juli 2026, 23:11 UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

21. Juli 2026, 19:46 UTC

Social Media

Iovance Biotherapeutics shares are higher amid positive social media sentiment and favorable earnings reports from peers, including General Motors and Novartis.

20. Juli 2026, 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares are higher today, with significant trading volume reaching 23.48 million. The stock has fluctuated between 4.44 and 5.07 during the session.

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

31.01% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD 31.01%

Hoch 13 USD

Tief 6 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Iovance Biotherapeutics Inc – Dist abgegeben haben.

Stimmung

By Acuity

152 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.